复星医药(02196) - 2024 H2 - 电话会议演示

Investor Presentation 2024 Report Prepared in accordance with China Accounting Standards Contents 1 Performance Highlights and Financial Review 2 Innovation and Internationalization 3 Pharmaceutical 4 Med Tech 5 Healthcare Services 6 Appendix Performance Highlights and Financial Review 2024 Financial Review (1/2) Revenue v RMB 41,067 million (-0.80%YoY) R&D Expense RMB 3,644 million (-16.15%YoY) Net Operating Cash Flow RMB 4,470 million (+31.13%YoY) Net Profit Attributable to Shareholders RMB 2,770 million ...